Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns.

Brunasso, A. M. G., Burlando, M., Amoruso, F., Arancio, L., Malara, G., Manzo, R., Montesu, M. A., Caldarola, G., Risankizumab: Daily Practice Experience of High Need Patients, <<BIOMEDICINES>>, 2023; 11 (6): N/A-N/A. [doi:10.3390/biomedicines11061769] [https://hdl.handle.net/10807/261989]

Risankizumab: Daily Practice Experience of High Need Patients

Caldarola, Giacomo
2023

Abstract

Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns.
2023
Inglese
Brunasso, A. M. G., Burlando, M., Amoruso, F., Arancio, L., Malara, G., Manzo, R., Montesu, M. A., Caldarola, G., Risankizumab: Daily Practice Experience of High Need Patients, <<BIOMEDICINES>>, 2023; 11 (6): N/A-N/A. [doi:10.3390/biomedicines11061769] [https://hdl.handle.net/10807/261989]
File in questo prodotto:
File Dimensione Formato  
biomedicines-11-01769.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 6.09 MB
Formato Adobe PDF
6.09 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/261989
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact